Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancreatic function and ivacaftor pharmacokinetics in adults with cystic fibrosis
NL-OMON51011Recruiting
- Sponsor
- HagaZiekenhuis
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by HagaZiekenhuis. Primary endpoints: Ivacaftor AUC in pancreatic sufficient versus pancreatic insufficient patients, Ivacaftor Tmax in pancreatic sufficient versus pancreatic insufficient patients and 2 more. Started May 2021; status: recruiting.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON51011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51011.